| 引用本文: | 郦瑜洁,熊阳.松弛素治疗肝纤维化的研究进展[J].中国现代应用药学,2022,39(23):3171-3175. |
| LI Yujie,XIONG Yang.Research Progress of Relaxin in the Treatment of Liver Fibrosis[J].Chin J Mod Appl Pharm(中国现代应用药学),2022,39(23):3171-3175. |
|
| 摘要: |
| 肝纤维化是肝内细胞外基质异常增生而降解减少的一种失衡性沉积的病理结果，是多种慢性肝病向肝硬化进展的共同反应，现在还没有药物被批准用于肝纤维化临床治疗。目前，纤维化可逆性已被确定为抗纤维化药物的重要原则和靶点之一。松弛素治疗因其能减弱活化的肝星状细胞的纤维化特性并逆转已形成的纤维化而受到重视。本文从肝纤维化发病机制、治疗现状、松弛素的概述及其治疗机制进行综述，为拓展松弛素疗法提供依据和指导。 |
| 关键词: 松弛素 肝纤维化 应用前景 研究进展 |
| DOI：10.13748/j.cnki.issn1007-7693.2022.23.019 |
| 分类号:R961 |
| 基金项目:浙江省医药卫生科技计划(2021KY813)；国家级大学生创新创业训练计划(202110344032)；浙江省自然科学基金重点项目(LZ22H290001) |
|
| Research Progress of Relaxin in the Treatment of Liver Fibrosis |
|
LI Yujie1, XIONG Yang1,2
|
|
1.College of Pharmacy, Zhejiang Chinese Medical University, Hangzhou 311403, China;2.Academy of Chinese Medical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China
|
| Abstract: |
| Liver fibrosis is a pathological result of an imbalanced deposition of abnormal growth and decreased degradation of the extracellular matrix in the liver, which is a common response to the progression of multiple chronic liver diseases to cirrhosis. To date, no drug has been approved for clinical use against liver fibrosis. At present, fibrosis reversibility has been identified as one of the most important principles and targets of antifibrotic drugs. Relaxin therapy is valued for its ability to attenuate the fibrotic properties of activated hepatic stellate cells and reverse established fibrosis. This research is reviewed from the pathogenesis of liver fibrosis, the current status of treatment, the overview of relaxin and its treatment mechanism to provide a basis and guidance for the further application of relaxin therapy. |
| Key words: relaxin liver fibrosis further application research progress |
